Cystic glandular dilatationdichotomic · patients with uterine fibroids
Mifepristone (50 mg/1 day after/3 months) may leads to higher cystic glandular dilatationdichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (5 mg/day/6 months) showed no clear difference in relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
Leiomyoma volume (mL) · patients with uterine fibroids
1 finding from 1 review
Uterine volume (cm³) · patients with uterine fibroids
1 finding from 1 review
Relief of bleedingdichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) may leads to higher relief of bleedingdichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of pelvic paindichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) showed no clear difference in relief of pelvic paindichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of dysmenorrhoeadichotomic · patients with uterine fibroids
Mifepristone (10 mg/day/3 months) may leads to higher relief of dysmenorrhoeadichotomic compared with placebo (low certainty).
1 finding from 1 review
Relief of painful symptoms ‐ pelvic tenderness · patients with pain associated with endometriosis
GnRHas may leads to higher relief of painful symptoms ‐ pelvic tenderness compared with placebo (low certainty).
1 finding from 1 review
Pain score ‐ Overall at 4 weeks · patients with pain associated with endometriosis
1 finding from 1 review